From 5b6c4bed54fd27cc54e7687a73ff3e94a325eb3d Mon Sep 17 00:00:00 2001
From: ndwarshuis <ndwar@yavin4.ch>
Date: Sun, 25 Jul 2021 23:11:30 -0400
Subject: [PATCH] ENH split aim 2 into a and b

---
 tex/thesis.tex | 15 +++++++++++----
 1 file changed, 11 insertions(+), 4 deletions(-)

diff --git a/tex/thesis.tex b/tex/thesis.tex
index f78b3ad..504454b 100644
--- a/tex/thesis.tex
+++ b/tex/thesis.tex
@@ -478,9 +478,9 @@ cells compared to state-of-the-art beads using \invivo{} mouse models for
 
 In Chapter~\ref{background}, we provide additional background on the current
 state of T cell manufacturing and how the work in this dissertation moves the
-field forward. In Chapters~\ref{aim1},~\ref{aim2}, and~\ref{aim3} we present the
-work pertaining to Aims 1, 2, and 3 respectively. Finally, we present our final
-conclusions in Chapter~\ref{conclusions}.
+field forward. In Chapters~\ref{aim1},~\ref{aim2a},~\ref{aim2b}, and~\ref{aim3}
+we present the work pertaining to Aims 1, 2, and 3 respectively. Finally, we
+present our final conclusions in Chapter~\ref{conclusions}.
 
 \chapter{background and significance}\label{background}
 \section*{background}
@@ -1545,7 +1545,14 @@ immunotherapies are activated and expanded with either soluble mAbs or
 bead-immobilized mAbs, our system will likely serve as a drop-in substitution to
 provide these benefits.
 
-\chapter{aim 2}\label{aim2}
+\chapter{aim 2a}\label{aim2a}
+
+\section{introduction}
+\section{methods}
+\section{results}
+\section{discussion}
+
+\chapter{aim 2b}\label{aim2b}
 
 \section{introduction}
 \section{methods}